Clinical Trial Update: The Effect of Celecoxib on Neuroinflammation in MDD [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating celecoxib for reducing neuroinflammation in patients with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Neuroinflammation

Drugs mentioned

• Celecoxib (Celecoxib)

Snippet

Sponsor: Stony Brook University | Conditions: Major Depressive Disorder, Neuroinflammation | Phase 4 | Status: COMPLETED